Latest filings (excl ownership)
15F-12B
Securities registration termination (foreign)
30 Sep 22
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Sep 22
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Sep 22
25
Voluntary exchange delisting
20 Sep 22
6-K
Company announcement – No. 38 / 2022
7 Sep 22
6-K
Company announcement – No. 37 / 2022
31 Aug 22
6-K
Company Announcement – No. 36 / 2022
26 Aug 22
6-K
Current report (foreign)
10 Aug 22
6-K
Zealand Pharma launches long-term incentive program for Zealand’s Corporate Management and employees for 2022
2 Jun 22
S-8
Registration of securities for employees
25 May 22
6-K
Company announcement – No. 22 / 2022
24 May 22
6-K
Company announcement – No. 21 / 2022
20 May 22
6-K
Interim report for Q1 2022
16 May 22
6-K
Company announcement – No. 14 / 2022
22 Apr 22
20-F/A
2021 FY
Annual report (foreign) (amended)
5 Apr 22
6-K
Company announcement – No. 10 / 2022
30 Mar 22
20-F
2021 FY
Annual report (foreign)
24 Mar 22
6-K
Focused on Growing our Most Valuable Asset Zealand Pharma Annual Report 2021 Company reg. no. 20045078
22 Mar 22
6-K
Full Year Results for 2021
14 Mar 22
6-K
Company announcement – No. 8/ 2022
14 Mar 22
6-K
Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital
15 Dec 21
6-K
Company announcement – No. 70/ 2021
22 Nov 21
6-K
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
19 Nov 21
6-K
Company announcement – No. 67/ 2021
12 Nov 21
6-K
Current report (foreign)
5 Nov 21
S-8
Registration of securities for employees
4 Oct 21
6-K
Current report (foreign)
1 Oct 21
6-K
New Employee Elected Director to the board of Zealand Pharma A/S
7 Sep 21
6-K
Current report (foreign)
26 Aug 21
6-K
Current report (foreign)
13 Aug 21
6-K
Current report (foreign)
30 Jul 21
6-K
Current report (foreign)
21 Jul 21
6-K
Current report (foreign)
21 Jul 21
6-K
Current report (foreign)
12 Jul 21
6-K
Current report (foreign)
29 Jun 21
6-K
Current report (foreign)
28 Jun 21
6-K
Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE® (dasiglucagon) injection
25 Jun 21
6-K
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH
4 Jun 21
6-K
Current report (foreign)
27 May 21
6-K
Current report (foreign)
17 May 21
Latest ownership filings
SC 13G/A
VAN HERK INVESTMENTS B.V.
14 Feb 22
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
3 Feb 21
SC 13G/A
VAN HERK INVESTMENTS B.V.
29 Jan 21
SC 13G/A
Zealand Pharma A/S
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
28 Jan 20
SC 13G/A
Zealand Pharma A/S
18 Sep 19
SC 13G/A
Zealand Pharma A/S
17 Sep 19
SC 13G/A
Zealand Pharma A/S
14 Feb 19
SC 13G/A
Zealand Pharma A/S
12 Feb 19
SC 13G
Zealand Pharma A/S
13 Jul 18
SC 13G
Zealand Pharma A/S
8 Feb 18